NeuroSense Therapeutics Ltd. (NRSN)Healthcare | Biotechnology | Herzliya, Israel | NasdaqCM
0.71 USD
+0.00
(0.424%)
⇧
(April 20, 2026, 4 p.m.
EDT)
Short-term: ★★★☆☆ | Long-term: ☆☆☆☆☆ | Dividends: ☆☆☆☆☆ |
Hot Take | April 19, 2026, midnight EDT
Speculative biotech turnaround play with zero cash balance and negative book value; strong buy analyst consensus is priced in against a backdrop of fundamental distress and patent announcements failing immediate monetization, while 20+ year losses signal total equity risk despite a 1.9% directional forecast model. |
| Model | MAE |
|---|---|
| AutoETS ✓ | 0.177297 |
| AutoTheta | 0.185477 |
| AutoARIMA | 0.190306 |
| MSTL | 0.214415 |
Forecast horizon: 45 days | Selected: AutoETS
| Forecast Reliability | |
|---|---|
| Score | 43% |
| H-stat | 12.02 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.432 |
| Excess Kurtosis | -0.95 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Market Cap | 25,098,366 |
| Forward P/E | -1.41 |
| Beta | 1.68 |
| Website | https://www.neurosense-tx.com |
| Attribute | Value |
|---|---|
| 52 Week Change | -0.29702967 |
| Address1 | Building B |
| Address2 | 11 HaMenofim Street |
| All Time High | 8.18 |
| All Time Low | 0.4 |
| Ask | 0.936 |
| Ask Size | 2 |
| Average Analyst Rating | 1.0 - Strong Buy |
| Average Daily Volume10 Day | 109,750 |
| Average Daily Volume3 Month | 163,990 |
| Average Volume | 163,990 |
| Average Volume10Days | 109,750 |
| Beta | 1.678 |
| Bid | 0.497 |
| Bid Size | 2 |
| Book Value | -0.048 |
| City | Herzliya |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Country | Israel |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 0.71 |
| Current Ratio | 0.309 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,774,915,200 |
| Day High | 0.7299 |
| Day Low | 0.7015 |
| Display Name | NeuroSense Therapeutics |
| Earnings Timestamp End | 1,751,976,000 |
| Earnings Timestamp Start | 1,750,762,740 |
| Ebitda | -11,069,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -2.268 |
| Enterprise Value | 25,102,368 |
| Eps Current Year | -0.305 |
| Eps Forward | -0.505 |
| Eps Trailing Twelve Months | -0.44 |
| Esg Populated | 0 |
| Exchange | NCM |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 0.82744 |
| Fifty Day Average Change | -0.117440045 |
| Fifty Day Average Change Percent | -0.14193179 |
| Fifty Two Week Change Percent | -29.702967 |
| Fifty Two Week High | 2.6 |
| Fifty Two Week High Change | -1.8899999 |
| Fifty Two Week High Change Percent | -0.72692305 |
| Fifty Two Week Low | 0.63 |
| Fifty Two Week Low Change | 0.07999998 |
| Fifty Two Week Low Change Percent | 0.1269841 |
| Fifty Two Week Range | 0.63 - 2.6 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,639,060,200,000 |
| Float Shares | 26,212,947 |
| Forward Eps | -0.505 |
| Forward P E | -1.4059405 |
| Free Cashflow | -3,869,125 |
| Full Exchange Name | NasdaqCM |
| Full Time Employees | 17 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Gross Margins | 0.0 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.18663 |
| Held Percent Institutions | 0.00979 |
| Implied Shares Outstanding | 35,349,813 |
| Industry | Biotechnology |
| Industry Disp | Biotechnology |
| Industry Key | biotechnology |
| Ipo Expected Date | 2,021-12-09 |
| Is Earnings Date Estimate | 1 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Long Business Summary | NeuroSense Therapeutics Ltd., a clinical-stage biotechnology company, focuses on discovering and developing treatments for patients suffering from neurodegenerative diseases in the United States and internationally. The company's lead product is PrimeC, an extended-release oral formulation of a fixed-dose combination of ciprofloxacin and celecoxib, currently under Phase 2b/3 clinical trials for the treatment of amyotrophic lateral sclerosis, and completed Phase 2 clinical trials for the treatment of Alzheimer's, as well as under preclinical studies for the treatment of Parkinson's disease. Its preclinical pipeline includes StabiliC for the treatment of Parkinson's disease; and CogniC for the treatment of Alzheimer's disease. NeuroSense Therapeutics Ltd. was incorporated in 2017 and is headquartered in Herzliya, Israel. |
| Long Name | NeuroSense Therapeutics Ltd. |
| Market | us_market |
| Market Cap | 25,098,366 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_551904618 |
| Most Recent Quarter | 1,767,139,200 |
| Net Income To Common | -11,125,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 25,098,367 |
| Number Of Analyst Opinions | 4 |
| Open | 0.7024 |
| Operating Cashflow | -7,671,000 |
| Operating Margins | 0.0 |
| Payout Ratio | 0.0 |
| Phone | 972 9 799 6183 |
| Pre Market Change | 0.009000003 |
| Pre Market Change Percent | 1.2829655 |
| Pre Market Price | 0.7105 |
| Pre Market Time | 1,776,772,778 |
| Previous Close | 0.707 |
| Price Eps Current Year | -2.3278687 |
| Price Hint | 4 |
| Price To Book | -14.791666 |
| Profit Margins | 0.0 |
| Quick Ratio | 0.079 |
| Quote Source Name | Nasdaq Real Time Price |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.0 |
| Region | US |
| Regular Market Change | 0.0029999614 |
| Regular Market Change Percent | 0.42432266 |
| Regular Market Day High | 0.7299 |
| Regular Market Day Low | 0.7015 |
| Regular Market Day Range | 0.7015 - 0.7299 |
| Regular Market Open | 0.7024 |
| Regular Market Previous Close | 0.707 |
| Regular Market Price | 0.71 |
| Regular Market Time | 1,776,715,200 |
| Regular Market Volume | 148,274 |
| Return On Assets | -2.47301 |
| Return On Equity | -21.749762 |
| Sand P52 Week Change | 0.34445214 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Shares Outstanding | 35,349,813 |
| Shares Percent Shares Out | 0.0178 |
| Shares Short | 594,593 |
| Shares Short Previous Month Date | 1,772,150,400 |
| Shares Short Prior Month | 503,652 |
| Short Name | NeuroSense Therapeutics Ltd. |
| Short Percent Of Float | 0.0218 |
| Short Ratio | 3.33 |
| Source Interval | 15 |
| Symbol | NRSN |
| Target High Price | 14.0 |
| Target Low Price | 3.0 |
| Target Mean Price | 8.375 |
| Target Median Price | 8.25 |
| Total Cash | 166,000 |
| Total Cash Per Share | 0.005 |
| Total Debt | 170,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -0.44 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 1.106375 |
| Two Hundred Day Average Change | -0.396375 |
| Two Hundred Day Average Change Percent | -0.3582646 |
| Type Disp | Equity |
| Volume | 148,274 |
| Website | https://www.neurosense-tx.com |
| Zip | 4,672,562 |